AparnaBio has achieved breakthrough technology that permits development of ligand-targeted nucleic acid nano-medicines, overcoming longstanding hurdles. Previously, targeted drug delivery with versatile in vivo tissue selectivity was elusive. One fundamental parameter emerged: a need to minimize pleotropic (i.e. non-specific) binding can be accomplished with a hydrophilic polymer coating on nanoparticles, before introduction of specific cell targeting. A protective coating alone permits nanoparticle localization at tumors with leaky blood vessels, called Enhanced Permeability and Retention (EPR). Our tissue targeting technology is applicable to a wide range of nanotechnology from antibody drug conjugates to nanoparticle therapeutics. The power of our technology also has enabled a revolutionary nanoparticle vaccine capability, a uniquely effective synthetic form of Virus-Like Particle vaccines (sVLP™). Another example is fungal targeted histatin analogues representing a systemic therapy breakthrough. But gene and RNAi therapy requires specific cell uptake and release. AparnaBio’s advanced tissue targeting and intracellular delivery opens the door to a wide range of powerful new therapeutic interventions promising to greatly improve treatment of life-threatening diseases.
Our tissue targeted, biodegradable NanoElectroPlex™ (NEP™) is applicable to a wide range of therapeutic classes. Current R&D focused on tumor targeted RNAi and gene therapy has generated a pipeline of innovative and powerful therapeutic candidates for treatment of cancers. One therapeutic has been developed that promises to greatly improve the treatment of a life-threatening cancer, an miRNA therapeutic candidate that shows dual activity, inhibiting both tumor and supporting angiogenesis (nano-DAMIR). Our success with this collaboration is advancing toward a product development partnership.
With our powerful and effective tissue targeting technology and success establishing R&D collaborations for development of therapeutic candidates, AparnaBio represents a attractive partner for academic and industry laboratories.
Tumor Targeting RNAi Therapeutics
Using our tissue targeting and NanoElectroPlex™ technologies, we have developed a pipeline of oncology therapeutics with an optimized integrin targeted biodegradable RNAi nanoparticle. This application of our therapeutic NanoElectroPlexTM technology employs biodegradable forms of our polyamide RNAi carriers, with low toxicity, to satisfy clinical use requirements.
Synthetic Virus-Like Particle (sVLP™) Nanoparticle Vaccines
AparnaBio has adapted NanoElectroPlex™ to package peptides and proteins, and with that capability achieved an innovative platform technology for vaccines: a synthetic biodegradable nanoparticle Virus-Like Particle system, sVLP™. Our sVLP™ is a major advancement over current vaccine technologies and is applicable to both prophylactic vaccines and immunotherapy applications.
With support from NIH, AparnaBio demonstrated the powerful capability of sVLP™ with an illustration project developing a dual antigen sVLP™ vaccine for a life-threatening bacterial disease, anthrax. Simultaneous packaging of weak and strong antigens was easily accomplished with sVLP™ as well as inclusion of a clinically validated synthetic adjuvant. This novel nanoparticle vaccine formulation produced a strong murine antibody response and importantly against both antigens, in fact a response far beyond any previously reported. Most importantly, the response was shown to be anthrax neutralizing by scientists in a US government laboratory. Thus this simple yet powerful sVLP™ technology is poised to develop vaccines for a wide range of infectious diseases, as well as therapeutic vaccines for cancer (immunotherapy).
The sVLP™ technology provides a simple to produce, multi-functional nanoparticle that can display large or small antigens on the surface, individually or in combinations, including synthetic or difficult to express antigens. It also incorporates powerful synthetic adjuvants within the nanoparticle so that the antigen and adjuvant can be delivered to the same antigen presenting cells. Antigens are incorporated into sVLP™ nanoparticles in a modular fashion, providing control of adjuvant to antigen ratio. These multifunctional capabilities have not been achieved with conventional VLP technology.
Invasive Fungal Infection Imaging and Therapy
Working with our collaborator at Univ. Maryland, AparnaBio has developed early stage therapeutic candidates attractive as a promising major advance for treatment of life-threatening invasive fungal infections, including drug resistant candida, aspergillus, and cryptococcus infections. These infections are a major nosocomial problem and have a poor survival outcome, resulting in a major unmet clinical need. Our ground-breaking advances in tissue targeting have resulted in therapeutic candidates that combine a novel mechanism of anti-fungal activity with infection site targeting. One of our targeted therapeutics utilizes a novel monoclonal antibody for a clinically validated fungal target for combination therapy with lipid-based amphotericin B formulations. Another exciting aspect of the infection site targeting is potential application for development of imaging agents to improve clinical diagnostics.
For more detailed information about our therapeutic products, please contact us.